AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Real-World Impact: Applying SABCS 2025 Advances in Community Oncology
By Sara Zhukovsky, MD; Christos Vaklavas, MD
How SABCS 2025 advances are transforming community oncology, with practical strategies to improve breast cancer screening, treatment adherence, survivorship care, and equitable access.
Real-World Impact: Applying SABCS 2025 Advances in Community Oncology
By Sara Zhukovsky, MD; Christos Vaklavas, MD
How SABCS 2025 advances are transforming community oncology, with practical strategies to improve breast cancer screening, treatment adherence, survivorship care, and equitable access.
Real-World Impact: Applying SABCS 2025 Advances in Community Oncology
By Sara Zhukovsky, MD; Christos Vaklavas, MD
How SABCS 2025 advances are transforming community oncology, with practical strategies to improve breast cancer screening, treatment adherence, survivorship care, and equitable access.
Nonprofit Binaytara Awards $50,000 to Cancer Researchers in Inaugural Impact Pitch Competition
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Nonprofit Binaytara Awards $50,000 to Cancer Researchers in Inaugural Impact Pitch Competition
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Nonprofit Binaytara Awards $50,000 to Cancer Researchers in Inaugural Impact Pitch Competition
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Reaching Out-of-School Maasai Girls With HPV Vaccination: A Community-Led Model for Cervical Cancer Prevention in Tanzania
By Dr. Innocent H. Peter Uggh, MD, MPH
A community-led HPV vaccination model in Tanzania targets out-of-school Maasai girls, addressing structural gaps in cervical cancer prevention through culturally grounded, scalable solutions.
Reaching Out-of-School Maasai Girls With HPV Vaccination: A Community-Led Model for Cervical Cancer Prevention in Tanzania
By Dr. Innocent H. Peter Uggh, MD, MPH
A community-led HPV vaccination model in Tanzania targets out-of-school Maasai girls, addressing structural gaps in cervical cancer prevention through culturally grounded, scalable solutions.
Reaching Out-of-School Maasai Girls With HPV Vaccination: A Community-Led Model for Cervical Cancer Prevention in Tanzania
By Dr. Innocent H. Peter Uggh, MD, MPH
A community-led HPV vaccination model in Tanzania targets out-of-school Maasai girls, addressing structural gaps in cervical cancer prevention through culturally grounded, scalable solutions.
Precision Frontiers in Hepatobiliary Oncology: Evaluating FGFR2 Selectivity and the Evolving Role of Immunotherapy
By Gentry George Teng King, MD
Expert analysis of FGFR2-targeted therapy in intrahepatic cholangiocarcinoma and the evolving role of immunotherapy in hepatocellular carcinoma, from adjuvant setbacks to perioperative and first-line advances.
Precision Frontiers in Hepatobiliary Oncology: Evaluating FGFR2 Selectivity and the Evolving Role of Immunotherapy
By Gentry George Teng King, MD
Expert analysis of FGFR2-targeted therapy in intrahepatic cholangiocarcinoma and the evolving role of immunotherapy in hepatocellular carcinoma, from adjuvant setbacks to perioperative and first-line advances.
Precision Frontiers in Hepatobiliary Oncology: Evaluating FGFR2 Selectivity and the Evolving Role of Immunotherapy
By Gentry George Teng King, MD
Expert analysis of FGFR2-targeted therapy in intrahepatic cholangiocarcinoma and the evolving role of immunotherapy in hepatocellular carcinoma, from adjuvant setbacks to perioperative and first-line advances.
Nepal’s Cancer Burden: A Systematic Review and Meta-Analysis of 15 Years of Evidence
By Dr. Roshan Kumar Mahato; Prof. Sujan Babu Marahatta; Dr. Kyaw Min Htike, DrPH
A comprehensive systematic review reveals Nepal’s rising cancer burden, highlighting late-stage diagnoses, financial toxicity, and the urgent need for national data to guide cancer control strategies.
Nepal’s Cancer Burden: A Systematic Review and Meta-Analysis of 15 Years of Evidence
By Dr. Roshan Kumar Mahato; Prof. Sujan Babu Marahatta; Dr. Kyaw Min Htike, DrPH
A comprehensive systematic review reveals Nepal’s rising cancer burden, highlighting late-stage diagnoses, financial toxicity, and the urgent need for national data to guide cancer control strategies.
Nepal’s Cancer Burden: A Systematic Review and Meta-Analysis of 15 Years of Evidence
By Dr. Roshan Kumar Mahato; Prof. Sujan Babu Marahatta; Dr. Kyaw Min Htike, DrPH
A comprehensive systematic review reveals Nepal’s rising cancer burden, highlighting late-stage diagnoses, financial toxicity, and the urgent need for national data to guide cancer control strategies.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD; Shipra Gandhi, MD, MS
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD; Shipra Gandhi, MD, MS
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Top Clinical Takeaways from SABCS 2025: What Oncologists Need to Know Now
By Zunairah Shah, MD; Shipra Gandhi, MD, MS
Key practice-changing insights from SABCS 2025, including earlier use of antibody–drug conjugates, the rise of oral SERDs, mutation-guided endocrine therapy, and evolving treatment sequencing across breast cancer subtypes.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancers: From Targeted Therapy to Advanced Treatment Strategies
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancers: From Targeted Therapy to Advanced Treatment Strategies
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.
Dr. Gentry King on Advances in Hepatocellular Carcinoma and Biliary Tract Cancers: From Targeted Therapy to Advanced Treatment Strategies
By The Cancer News Team
Dr. Gentry King reviews the latest advances in hepatocellular carcinoma and biliary tract cancers, highlighting FGFR2-targeted therapy, immune checkpoint inhibitors, and evolving strategies across BCLC stages.